Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Balic Marija |

Presentations at scientific and public conferences

Breitenstein, U; Wrobel, D; Guth, D; Zaiss, M; Terhaag, J; Zahn, MO; Perlova-Griff, L; Distelrath, A; Wuerstlein, R; Apel, K; Deuerling, N; Vannier, C; Bartsch, R; Jackisch, C; Mueller, V; Schmidt, M; Balic, M; Rinnerthaler, G; Lueftner, D; Zaman, K; Schwitter, M; Harbeck, N Extended adjuvant (adj) neratinib in HER2+/HR+ early breast cancer (eBC) in clinical routine - interim analysis of the multinational, prospective, non-interventional study (NIS) ELEANOR (n=300)
BREAST. 2025; 80: 103911 Doi: 10.1016/j.breast.2025.103911
Web of Science FullText FullText_MUG

 

Wimmer, K; Hlauschek, D; Balic, M; Pfeiler, G; Greil, R; Singer, CF; Halper, S; Steger, G; Suppan, C; Gampenrieder, SP; Helfgott, R; Egle, D; Filipits, M; Jakesz, R; Sölkner, L; Fesl, C; Gnant, M; Fitzal, F Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials
BREAST. 2025; 80: 103905 Doi: 10.1016/j.breast.2025.103905
Web of Science FullText FullText_MUG

 

Balic, M; Klocker, EV; Dobrić, N; Graf, R; Pancheri, L; Suppan, C; Jost, PJ; Heitzer, E; Dandachi, N High-sensitivity detection and broad genomic profiling in HR+/HER2- breast cancer: Final comparative results using targeted single-gene and broad-panel sequencing assays.
The Journal of Liquid Biopsy Supplement: November 2024. 2024; 5(100190):-6th Annual Congress of Liquid Biopsy: “Advancing and Accelerating Access of Liquid Biopsy” (ISLB 2024); NOV 23-25, 2024; Denver, Colorado, USA. [Poster]
FullText

 

Beheshti, M; Rinnerthaler, G; Farbod, A; Hitzl, W; Egle, D; Gampenrieder, SP; Bartsch, R; Balic, M; Greil, R; Gnant, M; Pirich, C Predictive role of baseline [18F]FDG PET/CT quantitative parameters for response to neoadjuvant treatment with atezolizumab, trastuzumab, pertuzumab and epirubicin in HER2-positive early breast cancer - a substudy of the ABCSG-52/ATHENE phase II trial
EUR J NUCL MED MOL I. 2024; 51: S481-S482. [Poster]
Web of Science

 

Dobrić, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Hasenleithner, S; Jost, PJ; Heitzer, E; Balic, M ctDNA profiling of HR+/HER2-low and HR+/HER2-0 metastatic breast cancer patients.
Molecular Oncology Supplement: EACR 2024: Innovative Cancer Science. 2024; 18(S1):i-ii.-EACR 2024 Congress: Innovative Cancer Science; JUN 10-13, 2024; Rotterdam, THE NETHERLANDS. [Poster]
FullText

 

Dobrić, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Hasenleithner, S; Jost, PJ; Heitzer, E; Balic, M Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients.
Proceedings of the 13th International Symposium on Circulating Nucleic Acids in Plasma and Serum (CNAPS). 2024; -13th International Symposium on Circulating Nucleic Acids in Plasma and Serum (CNAPS); MAR 4-6, 2024; Graz, AUSTRIA. [Poster]

 

Klocker, EV; Dobrić, N; Suppan, C; Graf, R; Foldi, J; Heitzer, E; Oesterreich, S; Lee, AV; Jost, PJ; Dandachi, N; Balic, M Comparison of lobular vs NST hormone receptor-positive metastatic breast cancer patients in early lines of treatment via comprehensive genomic profiling and whole-genome sequencing of circulating tumor DNA.
Proceedings of the San Antonio Breast Cancer Symposium 2024; Abstract Number: SESS-1277 . 2024; -San Antonio Breast Cancer Symposium 2024; DEC 10-13, 2024; San Antonio, TX; USA. [Poster]
FullText

 

Bartsch, R; Harbeck, N; Wrobel, D; Zaiss, M; Terhaag, J; Guth, D; Distelrath, A; Wuerstlein, R; Zahn, MO; Luftner, D; Schwitter, M; Balic, M; Jackisch, C; Muller, V; Rinnerthaler, G; Schmidt, M; Zaman, K; Schinkothe, T; Gorray, M; Breitenstein, U Interim analysis of ELEANOR (n=200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib
BREAST. 2023; 68: S20-S21. [Poster]
Web of Science

 

Bartsch, R; Harbeck, N; Wrobel, D; Zaiss, M; Terhaag, J; Guth, D; Distelrath, A; Würstlein, R; Zahn, MO; Lüftner, D; Schwitter, M; Balic, M; Jackisch, C; Müller, ; Rinnerthaler, G; Schmidt, M; Zaman, K; Schinköthe, T; Vannier, C; Breitenstein, U Interim analysis (n=200) of ELEANOR: a multi-national, prospective, non-interventional study among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib in the clinical routine
ONCOL RES TREAT. 2023; 46: 170-171. [Poster]
Web of Science

 

Dandachi, N; Graf, R; Pancheri, L; Dobric, N; Klocker, EV; Suppan, C; Jost, PJ; Heitzer, E; Balic, M Sensitive detection of circulating tumor DNA using targeted capture sequencing in advanced HR+/HER2- breast cancer patients.
6th ACTC - Advances in Circulating Tumor Cells Book of Abstracts. 2023; -6th ACTC - Advances in Circulating Tumor Cells; SEP 20-23, 2023; Skiathos, GREECE. [Poster]
FullText

 

Dandachi, N; Graf, R; Pancheri, L; Dobric, N; Klocker, EV; Suppan, C; Jost, PJ; Heitzer, E; Balic, M A head-to-head comparison for detecting PIK3CA mutations in circulating tumor DNA of advanced HR+/HER2-breast cancer patients
ANN ONCOL. 2023; 34: S1162-S1163.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); OCT 20-24, 2023; Madrid, SPAIN. Doi: 10.1016/j.annonc.2023.09.1289 [Poster]
Web of Science FullText FullText_MUG

 

Dobric, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Hasenleithner, S; Jost, PJ; Heitzer, E; Balic, M Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients
ANN ONCOL. 2023; 34: S387-S387.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); OCT 20-24, 2023; Madrid, SPAIN. Doi: 10.1016/j.annonc.2023.09.667 [Poster]
Web of Science FullText FullText_MUG

 

Dobric, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Hasenleithner, S; Jost, PJ; Heitzer, E; Balic, M. Comparison of ctDNA fraction and mutational profiles of plasma samples of HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients
6th ACTC - Advances in Circulating Tumor Cells Book of Abstracts. 2023; -6th ACTC - Advances in Circulating Tumor Cells; SEP 20-23, 2023; Skiathos, GREECE. [Poster]
FullText

 

Eberhard, A; Moser, T; Hammer, S; Glawitsch, L; Ziegler, L; Vlachos, G; Lang, K; Lazzeri, I; Bauernhofer, T; Balic, M; Loibner, M; Heitzer, E Development of analysis workflows for urinary cell-free DNA in malignant disease
Advances in Circulating Tumor Cells - ACTC 2023; SEP 20-23, 2023; Skiathos, Greece. 2023. [Poster]
FullText

 

Haas, D; Kröll, M; Dandachi, N; Dengler, M; Hrzenjak, A; Balic, M Modeling and overcoming clinically relevant resistance mechanisms to CDK4/6 inhibitor-based therapy in hormone receptor positive breast cancer cells
International Student Congress; Graz, AUSTRIA; . 2023. [Oral Communication]
FullText

 

Hilbers, F; Venet, D; Agostinetto, E; Benelli, M; Guerrero, A; Martins-Branco, D; Raimbault, A; Fimereli, D; Ferrando, L; Sommariva, S; Biagioni, C; Paoli, M; Llinas-Bertran, A; Dadiani, M; Zoppoli, G; Balic, M; Albanell, J; Vosberg, S; Irrthum, A; Salgado, R Characterization of the immune microenvironment in matched primary and metastatic breast cancer lesions from the AURORA study: BIG 14-01
J CLIN ONCOL. 2023; 41(16): [Poster]
Web of Science

 

Singer, CF; Konig, F; Kacerovsky-Strobl, S; Danzinger, S; Brunner, C; Suppan, C; Deutschmann, C; Balic, M; Greil, R; Egle, D; De Azambuja, E; Di Cosimo, S; Gnant, M Association of HER2/CEP17 ratio with pCR after HER2-directed neoadjuvant treatments in the phase III NeoALTTO trial
J CLIN ONCOL. 2023; 41(16): [Poster]
Web of Science

 

Wimmer, K; Hlauschek, D; Balic, M; Pfeiler, G; Strobl-Kacerovsky, S; Greil, R; Singer, CF; Halper, S; Steger, G; Suppan, C; Gampenrieder, SP; Helfgott, R; Egle, D; Filipits, M; Jakesz, R; Solkner, L; Fesl, C; Gnant, M; Fitzal, F Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
BREAST. 2023; 68: S123-S124. [Poster]
Web of Science

 

Balic, M; Posch, F; Bartsch, R Phase II Study of Neratinib and Trastuzumab plus -oral Vinorelbine in previously treated metastatic Her2 positive Breast Cancer
ONCOL RES TREAT. 2022; 45(SUPPL 2): 106-106. [Poster]
Web of Science

 

Harbeck, N; Wrobel, D; Zaiss, M; Guth, D; Distelrath, A; Terhaag, J; Lorenz, A; Bartsch, R; Breitenstein, U; Schwitter, M; Balic, M; Jackisch, C; Muller, V; Rinnerthaler, G; Schmidt, M; Zaman, K; Schinkothe, T; Luftner, D Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)
ANN ONCOL. 2022; 33: S157-S157. Doi: 10.1016/j.annonc.2022.03.091 [Poster]
Web of Science FullText FullText_MUG

 

Luftner, D; Bartsch, R; Breitenstein, U; Balic, M; Jackisch, C; Muller, V; Rinnerthaler, G; Schmidt, M; Schwitter, M; Zaman, K; Wrobel, D; Guth, D; Terhaag, J; Zaiss, M; Distelrath, A; Lorenz, A; Schinkothe, T; Harbeck, N Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)
ONCOL RES TREAT. 2022; 45(SUPPL 3): 20-21. [Poster]
Web of Science

 

Marme, F; Hanusch, C; Furlanetto, J; Morris, P; Link, T; Denkert, C; Fasching, PA; Jackisch, C; Antolin, S; Solbach, C; Aftimos, P; Huober, J; Untch, M; Balic, M; Reinisch, M; Blohmer, JU; Concalves, A; Rey, J; Buchele, T; Loibl, S Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT)
ONCOL RES TREAT. 2022; 45(SUPPL 3): 30-30. [Poster]
Web of Science

 

Marme, F; Hanusch, C; Furlanetto, J; Morris, P; Link, T; Denkert, C; Fasching, PA; Jackisch, C; Antolin, S; Solbach, C; Aftimos, P; Huober, J; Untch, M; Balic, M; Reinisch, M; Blohmer, JU; Goncalves, A; Rey, J; Buchele, T; Loibl, S Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment
ANN ONCOL. 2022; 33: S148-S149. Doi: 10.1016/j.annonc.2022.03.074 [Poster]
Web of Science FullText FullText_MUG

 

Pfeiler, G; Hlauschek, D; Mayer, EL; Deutschmann, C; Kacerovsky-Strobl, S; Martin, M; Meisel, JL; Zdenkowski, N; Loibl, S; Balic, M; Park, H; Prat, A; Isaacs, C; Machacek-Link, J; Schurmans, C; Theall, KP; Fesl, C; Dueck, AC; DeMichele, A; Gnant, M Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.
J CLIN ONCOL. 2022; 40(16): [Poster]
Web of Science

 

Singer, CF; Egle, D; Greil, R; Petru, E; Ohler, L; Balic, M; Tinchon, C; Pfeiler, G; Marhold, M; Brunner, C; Haider, K; Galid, A; Pluschnig, U; Haslbauer, F; Hubalek, M; Redl, A; Flatschacher, J; Uthman, S; Mraz, B; Bartsch, R REACH AUT: Efficacy and safety of first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC) from a real-world (RW) study: 3rd interim analysis
ANN ONCOL. 2022; 33: S217-S217. Doi: 10.1016/j.annonc.2022.03.214 [Poster]
Web of Science FullText FullText_MUG

 

Gampenrieder, SP; Rinnerthaler, G; Tinchon, C; Petzer, AL; Balic, M; Heibl, S; Zabernigg, A; Egle, D; Sandholzer, M; Roitner, F; Andel, J; Pichler, P; Hager, C; Hubalek, M; Knauer, M; Singer, CF; Greil, R Treatment landscape of HER2-positive metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry
ANN ONCOL. 2021; 32: S487-S488. Doi: 10.1016/j.annonc.2021.08.566 [Poster]
Web of Science FullText FullText_MUG

 

Klocker, EV; Posch, F; Suppan, C; Mischitz, N; Dengler, L; Steiner, D; Müller, HD; Jost, P; Dandachi, N; Balic, M Histopathological features and prognosis of early lobular breast cancer
Oncology Research and Treatment, Vol. 44, Suppl. 2, 2021. 2021; -Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie ; OCT 1-4, 2021; Berlin, GERMANY. [Poster]

 

Nicolay, L; Avian, A; Pristauz-Telsnigg, G; Balic, M; Tamussino, K; Trutnovsky, G; Gold, D Vaginal Laser Therapy versus Hyaluronic Acid Suppositories in Women with genitourinary Menopausal Syndrome after Breast Cancer Treatment: A randomized controlled Trial
GEBURTSH FRAUENHEILK. Kongressabstracts. 2021; 81(06):E27-E27.-Gemeinsamen Jahrestagung der OEGGG und der BGGF; JUN 2-5, 2021; Virtuell, DEUTSCHLAND. Doi: 10.1055/s-0041-1730508 [Onlinepräsentation]
Web of Science FullText FullText_MUG

 

Perakis, SO; Weber, S; Zhou, Q; Graf, R; Hojas, S; Riedl, JM; Gerger, A; Dandachi, N; Balic, M; Hoefler, G, Schuuring, E; Groen, HJM; Geigl, JB; Heiter, E; Speicher, MR Harnessing circulating tumor DNA to inform clinical decisions
Festival of Genomics & Biodata 2021; JAN 26-29, 2021; London, ENGLAND. 2021. [Onlinepräsentation]

 

Suppan, C; Zhou, Q; Jahn, S; Graf, R; Klocker, EV; Terbuch, A; Kashofer, K; Posch, F; Gerritsmann, H; Dandachi, N; Heitzer, E; Balic, M Comparison of liquid biopsy and tissue based detection of PIK3CAmutations in HR positive metastatic breast cancer patients
CANCER RES. 2021; 81(4): [Poster]
Web of Science

 

Christoph Suppan, Qing Zhou, Stephan Jahn, Ricarda Graf, Eva Valentina Klocker, Angelika Terbuch, Karl Kashofer, Florian Posch, Hanno Gerritsmann, Nadia Dandachi, Ellen Heitzer, Marija Balic Comparison of liquid biopsy and tissue based detection ofPIK3CAmutations in HR positive metastatic breast cancer patients.
SABCS 2020. 2020; -SABCS 2020; DEC 8-11, 2020; SAN ANTONIO, TEXAS, USA. [Poster]

 

Gampenrieder, SP; Rinnerthaler, G; Petzer, A; Tinchon, C; Fuchs, D; Balic, M; Heibl, S; Rumpold, H; Egle, D; Zabernigg, AF; Singer, CF; Andel, J; Hubalek, M; Knauer, M; Greil, R Landscape of HER2-low metastatic breast cancer (MBC): Results from the AGMT-MBC-Registry.
CANCER RES. 2020; 80(4):-San Antonio Breast Cancer Symposium; DEC 10-14, 2019; San Antonio, TX. Doi: 10.1158/1538-7445.SABCS19-P3-08-29 [Poster]
Web of Science FullText FullText_MUG

 

Perakis, SO; Weber, S; Graf, R; Zhou, Q; Riedl, JM; Dandachi, N; Balic, M; Gerger, A; Schuuring, E; Groen, HJ; Geigl, JB; Speicher, MR; Heitzer, E Identification of actionable targets in advanced cancer patients from circulating tumor DNA using clinical decision support platforms
CANCER RES. 2020; 80(16):-AACR Annual Meeting; JUN 22-24, 2020; ELECTR NETWORK. Doi: 10.1158/1538-7445.AM2020-1315 [Poster]
Web of Science FullText FullText_MUG

 

Perakis, SO; Weber, S; Zhou, Q; Graf, R; Hojas, S; Riedl, JM; Gerger, A; Dandachi, N; Balic, M; Hoefler, G; Schuuring, E; Groen, HJM; Geigl, JB; Heitzer, E; Speicher, MR Liquid biopsy profiling of advanced cancer patients for clinical decision support platform analysis.
ÖGPath Frühjahrstagung 2020; SEP 11-12, 2020; Vienna, AUSTRIA. 2020. [Oral Communication]

 

Posch, F; Barth, D; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Riedl, JM C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: A bi-center study.
ANN ONCOL. 2020; 31: S286-S286.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK. Doi: 10.1016/j.annonc.2020.08.234 [Poster] [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Tinchon, C; Fuchs, D; Balic, M; Heibl, S; Rumpold, H; Egle, D; Zabernigg, AF; Singer, CF; Andel, J; Hubalek, M; Knauer, M; Greil, R Prognosis of triple negative metastatic breast cancer (MBC): Results from the AGMT_MBC-Registry.
CANCER RES. 2020; 80(4):-San Antonio Breast Cancer Symposium; DEC 10-14, 2019; San Antonio, TX. Doi: 10.1158/1538-7445.SABCS19-P5-06-29 [Poster]
Web of Science FullText FullText_MUG

 

Suppan, C; Steiner, D; Klocker, VE; Posch, F; Henzinger, EC; Stoeger, H; Dandachi, N; Balic, M Safety and clinical evaluation of dual inhibition with pertuzumab and trastuzumab in HER-2-positive breast cancer patients.
J CLIN ONCOL. 2020; 38(15): [Onlinepräsentation]
Web of Science FullText

 

Suppan, C; Zhou, Q; Graf, R; Klocker, V; Terbuch, A; Dandachi, N; Heitzer, E; Balic, M Liquid biopsy-based detection of PIK3Ca mutations in HR positive metastastic breast cancer patients.
ANN ONCOL. 2020; 31: S41-S41.-ESMO Breast Cancer Virtual Meeting; MAY 23-24, 2020; ELECTR NETWORK. Doi: 10.1016/j.annonc.2020.03.213 [Poster] [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

Balic, M; Suppan, C; Brcic, I; Tiran, V; Mueller, DH; Posch, F; Ulz, P; Heitzer, E; Dandachi, N Untargeted assessment of tumour fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment
ANN ONCOL. 2019; 30: 110-+.-44th Congress of the European-Society-for-Medical-Oncology (ESMO); SEP 27-OCT 01, 2019; Barcelona, SPAIN. [Poster]
Web of Science

 

Dandachi, N; Absenger, G; Brcic, L; Kashofer, K; Terbuch, A; Jaritz, L; Stanzer, S; Balic, M Feasibility and clinical value of serial circulating tumor DNA testing in metastatic lung adenocarcinoma patients undergoing TKI treatment
ONCOL RES TREAT. 2019; 42: 213-213. [Poster]
Web of Science

 

Dandachi, N; Suppan, C; Brcic, L; Tiran, V; Mueller, DH; Posch, F; Ulz, P; Heitzer, E; Balic, M Monitoring therapy response and assessing prognosis by untargeted FAST-SeqS of circulating tumor DNA in metastatic breast cancer patients
ONCOL RES TREAT. 2019; 42: 41-41. [Poster]
Web of Science

 

Devyatko, Y; Filipits, M; Greil, R; Balic, M; Bago-Horvath, Z; Singer, C; Fitzal, F; Steger, G; Gray, B; Ferree, S; Fesl, C; Soelkner, L; von Minckwitz, G; Gnant, M The impact of clinical risk assessment versus PAM-50 ROR score on prognosis and therapeutic decision making in patients with hormone-receptor positive early stage breast cancer
CANCER RES. 2019; 79(4): Doi: 10.1158/1538-7445.SABCS18-P1-17-05 [Poster]
Web of Science FullText FullText_MUG

 

Fastner, G; Sedlmayer, F; Widder, J; Metz, M; Geinitz, H; Kapp, K; Solkner, L; Greil, R; Jakesz, R; Kwasny, W; Heck, D; Bjelic-Radisic, V; Balic, M; Stoger, H; Wieder, U; Zwrtek, R; Semmler, D; Horvath, W; Melbinger-Zeinitzer, E; Wiesholzer, M; Wette, V; Gnant, M Antihormones with or without irradiation in breast cancer: 10-year results of the ABCSG 8A trial
RADIOTHER ONCOL. 2019; 133: S132-S133.-38th Annual Meeting of the European-Society-for-Radiotherapy-and-Oncology (ESTRO); APR 26-30, 2019; Milan, ITALY. Doi: 10.1016/S0167-8140(19)30690-5 [Poster] [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

Fediuk, M; Fink-Neubock, N; Maier, A; Lindenmann, J; Balic, M; Smolle-Juttner, FM Bronchial Cancer - personalized
WIEN KLIN WOCHENSCHR. 2019; 131(19-20):508-508. [Oral Communication]
Web of Science

 

Filipits, M; Dubsky, P; Rudas, M; Greil, R; Balic, M; Fitzal, F; Bago-Horvath, Z; Singer, C; Hlauschek, D; Kronenwett, R; Bernhisel, R; Lancaster, J; Gnant, M Prediction of distant recurrence using EndoPredict among women with ER-positive, HER2-negative breast cancer with a maximum follow-up of 16 years
CANCER RES. 2019; 79(4):-San Antonio Breast Cancer Symposium; DEC 04-08, 2018; San Antonio, TX. Doi: 10.1158/1538-7445.SABCS18-P4-08-05 [Poster]
Web of Science FullText FullText_MUG

 

Gampenrieder, SPP; Rinnerthaler, G; Petzer, A; Tinchon, C; Fuchs, D; Balic, M; Heibl, S; Rumpold, H; Egle, D; Zabernigg, AF; Singer, CF; Andel, J; Hubalek, M; Knauer, M; Greil, R Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry
ANN ONCOL. 2019; 30: 126-+.-44th Congress of the European-Society-for-Medical-Oncology (ESMO); SEP 27-OCT 01, 2019; Barcelona, SPAIN. [Poster]
Web of Science

 

Heitzer, E; Balic, M ABCSG 34: Mutationsanalyse Primärtumore und ctDNA
ABCSG Jahestagung; NOV, 8-9; Saalfelden, AUT. 2019. [Oral Communication]

 

Posch, F; Glantschnig, T; Firla, S; Smolle, M; Balic, M; Moik, F; Stoeger, H; Zirlik, A; Pichler, M; Rainer, P Clinical utility of echocardiographic left-ventricular ejection fraction monitoring for cardiotoxicity risk assessment in patients with HER2+early breast cancer undergoing trastuzumab-based therapy
EUR HEART J. 2019; 40: 3844-3844.-ESC Congress / World Congress of Cardiology; AUG 31-SEP 04, 2019; Paris, FRANCE. [Poster]
Web of Science

 

Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Burgstaller, S; Voskova, D; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, CF; Petru, E; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, an ongoing phase I/II trial (AGMT MBC-10 trial)
CANCER RES. 2019; 79(4):-San Antonio Breast Cancer Symposium; DEC 04-08, 2018; San Antonio, TX. Doi: 10.1158/1538-7445.SABCS18-OT3-07-01 [Poster]
Web of Science FullText FullText_MUG

 

Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Tinchon, C; Fuchs, D; Balic, M; Heibl, S; Rumpold, H; Egle, D; Zabernigg, AF; Singer, CF; Andel, J; Hubalek, M; Knauer, M; Greil, R First data on overall survival of metastatic breast cancer patients in Austria according to breast cancer subtype: results from the AGMT MBC Registry
ONCOL RES TREAT. 2019; 42: 40-40.
Web of Science

 

Singer, CF; Oehler, L; Egle, D; Greil, R; Petru, E; Balic, M; Marhold, M; Pfeiler, G; Brunner, C; Kwasny, W; Galid, AA; Tinchon, C; Eisterer, W; Haslbauer, F; Hubalek, M; Redl, A; Hock, K; Hennebelle, M; Mraz, B; Steger, GG REACHAUT: First-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC) in the real-world setting.
J CLIN ONCOL. 2019; 37(15):-Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO); MAY 31-JUN 04, 2019; Chicago, IL. Doi: 10.1200/JCO.2019.37.15_suppl.e12527 [Poster]
Web of Science FullText FullText_MUG

 

Skok, K; Setaffy, L.; Posch, F.; Hammer, R.; Mali, U; Balic, M; Lax, S Analysis of breast carcinomas with ASCO/CAP 2013 equivocal HER2 status and with chromosome 17 monosomy in comparison with HER2 positive and negative groups : a single center study
-. 2019; 40: 692-692.-4th Joint Annual Meeting of the Swiss and Austrian Societies of Pathology; NOV 7-9, 2019; Luzern, SWITZERLAND. [Poster]
FullText

 

Balic, M Olaparib beim metastasierten Mammakarzinom – aktuelle Datenlage und Kriterien für die Patientinnenselektion
Jahrestagung der Österreichischen Gesellschaft für Senologie; Sep 27-29, 2018; Graz. 2018. [Keynote lecture]

 

Balic, M „Antiresorptive Therapie des Mammakarzinoms. Welche ist am erfolgversprechendsten?“
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; Sep 28-Okt 02, 2006; Vienna, Austria. 2018. [Science to Public]

 

Balic, M Rolle von CDK4/6 Inhibitoren in frühen Linien beim metastasiertem HR+HER2-Mammakarzinom
Jahrestagung der Österreichischen Gesellschaft für Senologie ; Sep 27-29, 2018; Graz. 2018. [Keynote lecture]

 

Balic, M; Mueller, DH; Hammer, R; Gumpoldsberger, M; Suppan, C; Posch, F; Stoeger, H; Dandachi, N; Prein, K; Hauser, H; Lax, S Independent evaluation of prognostic value of residual cancer burden (RCB) score on disease free and overall survival of breast cancer patients treated with neoadjuvant systemic treatment at a single institution
CANCER RES. 2018; 78(4):-San Antonio Breast Cancer Symposium; DEC 05-09, 2017; San Antonio, TX. [Poster]
Web of Science

 

Dubsky, PC; Fesl, C; Singer, CF; Pfeiler, G; Kronenwett, R; Hubalek, M; Bartsch, R; Stoeger, H; Pichler, A; Petru, E; Bjelic-Radisic, V; Greil, R; Rudas, M; Tea, MKM; Wette, V; Petzner, AL; Sevelda, P; Egle, D; Fitzal, F; Exner, R; Jakesz, R; Balic, M; Tinchon, C; Bago-Horvath, Z; Lax, S; Regitnig, P; Gnant, M; Filipits, M The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2-breast cancer patients from ABCSG 34
CANCER RES. 2018; 78(4):-San Antonio Breast Cancer Symposium; DEC 05-09, 2017; San Antonio, TX. [Oral Communication]
Web of Science

 

Filipits, M; Rudas, M; Singer, C; Bago-Horvath, Z; Greil, R; Balic, M; Lax, SF; Wu, N; Zhao, S; Weidler, J; Bates, M; Hlauschek, D; Gnant, M; Dubsky, P mRNA expression of ER, PR, HER2 and Ki67 are concordant to central ihc and predict clinical outcome: A validation study from the ABCSG-6 biomarker cohort
ANN ONCOL. 2018; 29: 480-480.-43rd ESMO Congress (ESMO); OCT 19-23, 2018; Munich, GERMANY. [Poster]
Web of Science

 

Gasparovic, AC; Milkovic, L; Sitic, S; Pezdirc, I; Vrancic, J; Stanzer, S; Dandachi, N; Balic, M Role of 4-hydroxynonenal in communication between cancer stem cells and microenvironment
FREE RADICAL BIO MED. . 2018; 124: 563-563.-International HNE-Club Meeting; SEP, 2017; Graz, AUSTRIA. Doi: 10.1016/j.freeradbiomed.2018.05.025 [Oral Communication]
Web of Science FullText FullText_MUG

 

Gnant, M; Steger, G; Greil, R; Fitzal, F; Mlineritsch, B; Manfreda, D; Tausch, C; Balic, M; Dubsky, P; Moik, M; Thaler, J; Egle, D; Bjelic-Radisic, V; Selim, U; Exner, R; Singer, C; Melbinger-Zeinitzer, E; Haslbauer, F; Stoger, H; Helfgott, R; Sevelda, P; Trapl, H; Wette, V; Solkner, L; Jakesz, R A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial
CANCER RES. 2018; 78(4):-San Antonio Breast Cancer Symposium; DEC 05-09, 2017; San Antonio, TX. [Oral Communication]
Web of Science

 

Muller, HD; Posch, F; Gumpoldsberger, M; Suppan, C; Hammer, R; Hauser, H; Dandachi, N; Prein, K; Stoger, H; Lax, S; Balic, M Prognostic impact of the Residual Cancer Burden (RCB) index on recurrence-free survival of breast cancer patients recieving neoadjuvant therapy
ONCOL RES TREAT. 2018; 41: 297-298. [Poster]
Web of Science

 

Pereyra, D; Bee, A; Duerr, C; Lamm, C; Brostjan, C; Spittler, A; Starlinger, P; Steger, G; Balic, M; Gnant, M; Fitzal, F Pro-angiogenic profile after resection of primary tumour might be responsible for reduced outcome in patients with primary metastasized breast cancer
EUR J CANCER. 2018; 92: S137-S137.-11th European Breast Cancer Conference (EBCC); MAR 21-23, 2018; Barcelona, SPAIN. [Poster]
Web of Science

 

Pfeiler, G; Steger, GG; Egle, D; Greil, R; Fitzal, F; Wette, V; Balic, M; Haslbauer, F; Melbinger-Zeinitzer, E; Bjelic-Radisic, V; Bergh, J; Jakesz, R; Marth, C; Sevelda, P; Mlineritsch, B; Exner, R; Fesl, C; Frantal, S; Singer, CF; Gnant, M Fracture Risk after Stopping Adjuvant Denosumab in Hormone Receptor Positive Breast Cancer Patients on Aromatase Inhibitor Therapy - an Analysis of 3,425 Postmenopausal Patients in the Phase III ABCSG-18 trial
J BONE MINER RES. 2018; 33: 55-55.-Annual Meeting of the American-Society-for-Bone-and-Mineral-Research; SEP 28-OCT 01, 2018; Montreal, CANADA. [Keynote lecture]
Web of Science

 

Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Pusch, R; Fridrik, M; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, C; Bartsch, R; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, a phase I/II trial (AGMT MBC-10 trial)
CANCER RES. 2018; 78(4):-San Antonio Breast Cancer Symposium; DEC 05-09, 2017; San Antonio, TX. [Poster]
Web of Science

 

Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Pusch, R; Voskova, D; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, CF; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, an ongoing phase I/II trial (AGMT MBC-10 trial)
CANCER RES. 2018; 78(13):-Annual Meeting of the American-Association-for-Cancer-Research (AACR); APR 14-18, 2018; Chicago, IL. Doi: 10.1158/1538-7445.AM2018-CT160 [Poster]
Web of Science FullText FullText_MUG

 

Suppan, C; Brcic, I; Heitzer, E; Tiran, V; Mueller, HD; Auer, M; Cote, RJ; Datar, R; Dandachi, N; Balic, M Prognostic impact of tumor fractions in plasma assessed with mFAST-SeqS on overall survival of metastatic breast cancer undergoing systemic treatment
EUR J CANCER. 2018; 92: S136-S136.-11th European Breast Cancer Conference (EBCC); MAR 21-23, 2018; Barcelona, SPAIN. [Poster]
Web of Science

 

Balic, M Prevention von Frakturen
26. Jahrestagung der ABCSG; 18.-19.11.2017; Saalfelden. 2017. [Keynote lecture]

 

Balic, M Her2 im Wandel der Zeit
Her2 Expertenforum; 02.02.2017; Wien. 2017. [Keynote lecture]

 

Balic, M Translational studies in ABCSG 18
International advisory board for ABCSG 18 osteospecific analyses; 24.01.2017; Vienna, Austria. 2017. [Oral Communication]

 

Balic, M Post San Antonio: Systemische Behandlung vom frühen Brustkrebs und prognostische Faktoren
4. Post SABCS; 13.01.2017; Wien. 2017. [Keynote lecture]

 

Balic, M Anti-HER2 therapy in eBC
; 16.03.2017; Wien. 2017. [Keynote lecture]

 

Balic, M New options- new data: Aktuelle Studienlage zu CDK 4/6 Inhibitoren
; 02.03.2017; Graz. 2017. [Keynote lecture]

 

Balic, M Therapie des triple negativen metastasierten Mammakarzinoms
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie 2017; Sep 29- Okt 3, 2017; Stuttgart, Deutschland. 2017. [Keynote lecture]

 

Balic, M N. mammae Triple Negativ metastasiert
4. Kärntner u. Steirischen Onkologiesymposium; , 9.-10.6.2017 ; Klagenfurt. 2017. [Keynote lecture]

 

Balic, M Metronome Chemotherapie: Hintergrund, Bedeutung, aktuelle Studien
4. WOMEN‘S HEALTH Symposium Neues zum metastasierten Mammakarzinom; 12.-13.05.2017; Oehningen, Deutschland. 2017. [Keynote lecture]

 

Balic, M Immuntherapie bei Brustkrebs
26. Jahrestagung der ABCSG; 18.-19.11.2017; Saalfelden, Austria. 2017. [Keynote lecture]

 

Balic M Selected Abstracts von San Antonio Breast Cancer Symposium
Post SABCS; 13.01.2017; WIen. 2017. [Keynote lecture]

 

Balic, M; Mueller, HD; Hammer,R; Gumpoldsberger, M; Suppan,C; Posch,F; Stoeger, H; Dandachi, N; Prein, K; Hauser, H; Lax, S; Independent evaluation of prognostic value of residual cancer burden (RCB) score on disease free and overall survival of breast cancer patients treated with neoadjuvant systemic treatment at a single institution
Proceedings of the 40th San Antonio Breast Cancer Symposium Abstracts2View™ Portal. 2017; -SABACS; DEC 5-9 2017; San Antonio, USA. [Poster]
FullText

 

Bjelic-Radisic, V; Singer, CF; Pfeiler, G; Hubalek, M; Bartsch, R; Stoger, H; Pichler, A; Petru, E; Greil, R; Wette, V; Petzer, A; Sevelda, P; Egle, D; Dubsky, P; Fitzal, F; Jakesz, R; Balic, M; Frantal, S; Solkner, L; Gnant, M Quality-of-life results from a randomized, phase-II-study of the therapeutic cancer vaccine L-BLP25 (Stimuvax (R)) in the preoperative treatment of women with primary breast cancer (ABCSG-34)
ANN ONCOL. 2017; 28: -42nd European-Society-for-Medical-Oncology Congress (ESMO); SEP 08-12, 2017; Madrid, SPAIN. [Oral Communication]
Web of Science

 

Dubsky, P; Fesl, C; Singer, CF; Pfeiler, G; Kronenwett, R; Hubalek' M; Bartsch, R; Stoeger, H; Pichler, A; Petru, E; Bjelic-Radisic, V; Greil, R; Rudas, M; Tea, M-KM; Wette, V; Petzer, AL; Sevelda, P; Egle, D; Fitzal, F; Jakesz, R; Balic, M; Tinchon, C; Bago- Horvath, Z; Regitnig, P; Gnant, M, Filipits, M The Endopredict Score Predicts Residual Cancer Burden to Noeadjuvant Chemotherapy and to Neo-Endocrine Therapy in HR+/Her2- Breast Cancer Patients from ABCSG 34
https://www.sabcs.org/2017. 2017; -San Antonio Breast Cancer Symposium; December 05-09th, 2017; San Antonio, TX, USA. [Oral Communication]
FullText

 

Heitzer, E; ,Auer, M; Suppan, C; Dandachi, N; Balic, M. Changes in ctDNA levels established with the untargeted mFAST-SeqS method reflect response to therapy in metastasized breast cancer patients
Proceedings of the 24EACR. 2017; -EACR; JUL 9-12, 2016; Manchester, UK. [Poster]
FullText

 

Rinnerthaler, G; Gampenrieder, SP; Voskova, D; Petzer, A; Hubalek, M; Petru, E; Hartmann, B; Andel, J; Balic, M; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PFS results of a phase II trial (AGMT MBC-6)
CANCER RES. 2017; 77: -San Antonio Breast Cancer Symposium; DEC 06-10, 2016; San Antonio, TX. Doi: 10.1158/1538-7445.SABCS16-P5-15-13 [Poster]
Web of Science FullText FullText_MUG

 

Singer, CF; Pfeiler, G; Hubalek, M; Bartsch, R; Stoeger, H; Pichler, A; Petru, E; Greil, R; Rudas, M; Tea, MK; Wette, V; Petzer, AL; Sevelda, P; Egle, D; Dubsky, PC; Balic, M; Tinchon, C; Bago-Horvath, Z; Frantal, S; Michael, G Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase-II study (ABCSG-34)
CANCER RES. 2017; 77: -San Antonio Breast Cancer Symposium; DEC 06-10, 2016; San Antonio, TX. Doi: 10.1158/1538-7445.SABCS16-P6-10-01 [Poster]
Web of Science FullText FullText_MUG

 

Singer, CF; Tan, YY; Fitzal, F; Steger, GG; Egle, D; Reiner, A; Rudas, M; Gruber, C; Bartsch, R; Fridrik, M; Seifert, M; Exner, R; Balic, M; Bago-Horvath, Z; Filipits, M; Gnant, M Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer
CANCER RES. 2017; 77: -San Antonio Breast Cancer Symposium; DEC 06-10, 2016; San Antonio, TX. Doi: 10.1158/1538-7445.SABCS16-P1-09-10 [Poster]
Web of Science FullText FullText_MUG

 

Suppan, C; Tiran, V; Heitzer, E; Auer, M; Cote, RJ; Datar, RH; Dandachi, N; Balic, M Serial blood draws in metastatic breast cancer patients undergoing systemic treatment analysed by size based CTC detection and mFAST Seq cell free DNA analysis
EUR J CANCER. 2017; 72: S39-S40. Doi: 10.1016/S0959-8049(17)30211-3 [Poster]
Web of Science FullText FullText_MUG

 

Tiran, V; Lindenmann, J; Stanzer, S; Brcic, L; Heitzer, E; Ghaffari-Tabrizi, N; Fink-Neuböck, N; Popper, H; Dandachi, N; Balic, M Patient-derived Lung Adenocarcinoma Cells challenge the association of Cancer Stem Cells with Epithelial to Mesenchymal Transition.
OeGHO Frühjahrstagung; APR 6-8, 2017; Bregenz, AUSTRIA. 2017. [Poster]

 

Balic, M ABCSG 18: Ergebnisse zum ontologischen Endpunkt
ABCSG Homepage. 2016; -25te Jahrestagung der ABCSG; 4.-5.11.2016; Saalfelden, Austria. [Keynote lecture]

 

Balic, M „Der interessante Fall“: Second Line
Mamma Diskurs; 23.11.2o16; Wien. 2016. [Oral Communication]

 

Balic, M, Heitzer, E Klinische Anwendbarkeit von zirkulierender DNA
... 2016; -Combating Breast Cancer; 11.-12.11.; Duesseldorf, Germany. [Keynote lecture]

 

Balic M, Heitzer E Klinische Anwendbarkeit von zirkulierender DNA
ABCSG Homepage. 2016; -25te Jahrestagung der ABCSG; 4.-.5.11.2016; Saalfelden, Austria. [Keynote lecture]

 

Gabriel Rinnerthaler, Simon Peter Gampenrieder, Daniela Voskova, Andreas L. Petzer, Michael Hubalek, Edgar Petru, Bernd Hartmann, Johannes Andel, Marija Balic, Hanno Ulmer, Thomas Melchardt, Brigitte Mlineritsch, Richard Greil Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Efficacy results of a phase II trial (AGMT MBC-6)
Journal of Clinical Oncology. 2016; -ASCO; 02.-06.06.2016; Chicago. [Poster]

 

Gnant, M; Pfeiler, G; Dubsky, PC; Hubalek, M; Greil, R; Jakesz, R; Wette, V; Balic, M; Haslbauer, F; Melbinger-Zeinitzer, E; Bjelic-Radisic, V; Artner-Matuschek, S; Fitzal, F; Marth, C; Sevelda, P; Mlineritsch, B; Steger, GG; Manfreda, D; Exner, R; Egle, D; Bergh, J; Kainberger, F; Talbot, S; Warner, D; Fesl, C; Singer, CF The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial
CANCER RES. 2016; 76: -38th Annual CTRC-AACR San Antonio Breast Cancer Symposium; DEC 08-12, 2015; San Antonio, TX. Doi: 10.1158/1538-7445.SABCS15-S2-02 [Keynote lecture]
Web of Science FullText FullText_MUG

 

Helmut H. Popper, Luka Brcic, Stefanie Stanzer, Gudrun Absenger, Joerg Lindenmann, Mohamed Al-Effah, Marija Balic Evaluation of immune tolerance mechanisms in pulmonary squamous cell and adenocarcinomas – how to interfere beyond PDL1 blockade
AACR Abstract book. 2016; -AACR, Annual Meeting ; April 2016; New Orleans, USA. [Poster]

 

Rinnerthaler, G; Gampenrieder, SP; Fridrik, M; Petzer, A; Hubalek, M; Petru, E; Jager, T; Andel, J; Balic, M; Ulmer, H; Mlineritsch, B; Greil, R Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Stage 1 results of a phase II trial (AGMT MBC-6)
CANCER RES. 2016; 76: -38th Annual CTRC-AACR San Antonio Breast Cancer Symposium; DEC 08-12, 2015; San Antonio, TX. Doi: 10.1158/1538-7445.SABCS15-P1-13-10 [Poster]
Web of Science FullText FullText_MUG

 

Rinnerthaler, G; Gampenrieder, SP; Voskova, D; Petzer, A; Hubalek, M; Petru, E; Hartmann, B; Andel, J; Balic, M; Melchardt, T; Mlineritsch, B; Greil, R Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6)
ANN ONCOL. 2016; 27: -41st Congress of the European-Society-for-Medical-Oncology (ESMO); OCT 07-11, 2016; Copenhagen, DENMARK. Doi: 10.1093/annonc/mdw365.18 [Poster]
Web of Science FullText FullText_MUG

 

Rinnerthaler G, Gampenrieder SP, Voskova D, Petzer A, Hubalek M, Petru E, Hartmann B, Andel J, Balic M, Melchardt T, Ulmer H, Mlineritsch B, Greil R Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PFS results of a phase II trial (AGMT MBC-6)
https://www.sabcs.org/Portals/SABCS2016/Documents/SABCS-2016-Abstracts.pdf?v=1. 2016; -San Antonio Breast Cancer Symposium; 06.-10.12.2016; San Antonio, TX, USA. [Poster]

 

Singer CF, Pfeiler G, Hubalek M, Bartsch R, Stoeger H, Pichler A, Petru E, Greil R, Rudas M, Tea M-KM, Wette V, Petzer AL, Sevelda P, Egle D, Dubsky PC, Balic M, Tinchon C, Bago-Horvath Z, Frantal S, Michael G Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase-II study (ABCSG-34)
https://www.sabcs.org/Portals/SABCS2016/Documents/SABCS-2016-Abstracts.pdf?v=1. 2016; -San Antonio Breast Cancer Symposium; 06.-10.12.2016; San Antonio, TX, USA. [Poster]

 

Singer CF, Tan YY, Fitzal F, Steger GG, Egle D, Reiner A, Rudas M, Gruber C, Bartsch R, Fridrik M, Seifert M, Exner R, Balic M, Bago-Horvath Z, Filipits M, Gnant M Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer
https://www.sabcs.org/Portals/SABCS2016/Documents/SABCS-2016-Abstracts.pdf?v=1. 2016; -San Antonio Breast Cancer Symposium; 06.-10.12.2016; San Antonio, TX, USA. [Poster]

 

Balic, M What is the role of resection of primary tumor in metastatic breast cancer? What is the role of cancer stem cells and circulating tumor cells and clinical state of the art
ONCOL RES TREAT. 2015; 38: 179-179.-Jahrestagung der DGHO, OeGHO, SGMO und SGH; 09.-13.10.2015; Basel. [Oral Communication]
Web of Science

 

Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF, on behalf of the Austrian Breast and Colorectal Cancer Study Group The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial
http://www.abstracts2view.com/sabcs15/search.php?search=do&intMaxHits=10&where%5B%5D=&andornot%5B%5D=&query=balic&condition=ANY&%23.x=0&%23.y=0&%23=Go. 2015; -San Antonio Breast Cancer Symposium; 2015; San Antonio, TX, USA. [Oral Communication]

 

Gnant, M; Pfeiler, G; Dubsky, PC; Hubalek, M; Greil, R; Jakesz, R; Wette, V; Balic, M; Haslbauer, F; Melbinger-Zeinitzer, E; Radisic, VB; Bergh, JCS; Fitzal, F; Egle, D; Mlineritsch, B; Steger, GG; Talbot, S; Warner, DJ; Fesl, C; Singer, CF Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial.
J CLIN ONCOL. 2015; 33(15):-Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO); MAY 29-JUN 02, 2015; Chicago, IL. Doi: 10.1200/jco.2015.33.15_suppl.504 [Oral Communication]
Web of Science FullText FullText_MUG

 

Steger, GG; Greil, R; Hubalek, M; Fridrik, MA; Singer, CF; Bartsch, R; Balic, M; Dubsky, P; Egle, D; Gampenrieder, SP; Pfeiler, G; Mayr, D; Czech, T; Rinnerthaler, G; Exner, R; Petzer, AL; Sevelda, P; Lang, A; Rudas, M; Krause, B; Seifert, M; Frantal, S; Zielinski, CC; Gnant, M Bevacizumab in combination with docetaxel plus trastuzumab +/- non-pegylated liposomal doxorubicin: Final results of ABCSG-32, a prospective, randomized phase II-study
CANCER RES. 2015; 75(9):-37th Annual CTRC-AACR San Antonio Breast Cancer Symposium; DEC 09-13, 2014; San Antonio, TX.
Web of Science

 

Suppan, C; Bauernhofer, T; Eisner, F; Stöger, H; Balic, M; Schöllnast, H; Liegl-Atzwanger, B; Efficacy of sorafenib in a patient with metastatic high grade thymic carcinoma
ÖGHO Frühjahrstagung; APR 10-12, 2014; Innsbruck, AUSTRIA. 2014. [Poster]

 

Suppan, C; Bjelic-Radisic, V; La Garde, M; Samonigg, H; Dandachi, N; Balic, M N/L Ratio does not have predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy
EUR J CANCER. 2014; 50: S193-S193.-9th European Breast Cancer Conference (EBCC); MAR 19-21, 2014; Glasgow, SCOTLAND. [Poster]
Web of Science

 

Suppan, C; Milkovic, L; Gasparovic, AC; Samonigg, H; Dandachi, N; Balic, M Higher levels of HNE are associated with disease aggressiveness and worse outcome in breast cancer patients
EUR J CANCER. 2014; 50: S70-S70.-9th European Breast Cancer Conference (EBCC); MAR 19-21, 2014; Glasgow, SCOTLAND. [Poster]
Web of Science

 

Suppan, C; Steger, G; Balic, M; Dandachi, N; Lang, A; Mlineritsch, B; Fesl,C; Samonigg, H; Gnat,M; Bauernhofer,T; Evaluation of soluble E-Cadherin as a predictive marker for response to preoperative systemic chemotherapy in early breast cancer
Annals of Oncology Supplement 2014. 2014; -IMPAKT; May 7-10, 2014; Brussels, Belgium. [Poster]

 

Tiran, V; Datar, R; Williams, A; Dandachi, N; Cote, RJ; Balic, M A feasibility study to evaluate microfilter based CTC enrichment and characterization
ACTC Meeting; Crete, Greece. 2014. [Poster]

 

Tiran, V; Treitler, N; Zidar, N; Peterlin Mašč, L; Kikelj, D; Balic,M and Dandachi, N Anti-tumoral Effect of a Novel Marine Alkaloid-Analogon on Breast Cancer Stem Cells.
COST Action 2014; März 27-29, 2014; Budapest, Hungary. 2014. [Poster]

 

Brunner, C; Jaeger, T; Suppan, C; Mueller-Holzner, E; Jasarevic, Z; Balic, M; Goebel, G; Marth, C; Stoeger, H; Samonigg, H; Hubalek,M; Lang, A; Cardiac safety and efficacy of concomitant liposomal doxorubicin, docetaxel, and trastuzumab as neoadjuvant therapy in HER2-overexpressing breast cancer: A retrospective analysis
ASCO 2013 Annual Meeting; MAY 31-JUNE 4, 2013; Chicago, USA. 2013. [Poster]

 

Heitzer E, Mach M, Filipits M, Balic M, Resel M, Graf R, Weißenbacher B, Lax S, Heitzer, E; Mach, M; Filipits, M; Balic, M; Resel, M; Graf, R; Weißenbacher, B; Lax, S; Samonigg, H; Gnant, M; Wrba, F; Greil, R; Dietze, O; Hofbauer, F; Böhm, G; Schaberl-Moser, R; Dandachi, N. Methylation of PCDH10, SPARC, and UCHL1 predicts survival and in stage II colorectal cancer patients.
http://gfhev.de/de/kongress/GfH_Tagung_2013_Abstractbook.pdf. 2013; -24. Jahrestagung der Deutschen Gesellschaft für Humangenetik ; MAR 20-22,2013; Dresden, GERMANY. [Poster]

 

Suppan, C; Bjelic-Radisic, V; La Guarde, M; Dandachi, N; Balic, M Neutrophil/Lymphocyte Ratio does not have predictive or prognostic value in breast cancer patients undergoing neoadjuvant systemic therapy
ONKOLOGIE. 2013; 36: 158-158. [Poster]
Web of Science

 

Suppan, C; Milkovic, L; Gasparovic, AC; Waeg, G; Dandachi, N; Balic, M Higher levels of HNE are associated with disease aggressiveness and worse outcome of breast cancer patients
ONKOLOGIE. 2013; 36: 176-176.
Web of Science

 

Heitzer, E; Marija, B; Resel, M; Graf, R; Weissenbacher, B; Schaberl-Moser, R; Dandachi, N; IDENTIFICATION OF PROGNOSTIC METHYLATION MARKERS IN PATIENTS WITH EARLY STAGE COLORECTAL CANCER.
ANN ONCOL. 2012; 23: 87-87.-14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO); JUN 27-30, 2012; Barcelona, SPAIN. [Poster]
Web of Science

 

Rossmann, C; Balic, M; Krippl, P; COMPARISON OF OVERALL SURVIVAL IN METASTATIC COLORECTAL CANCER PATIENTS - DAILY PRACTICE VERSUS RANDOMIZED TRIALS.
ANN ONCOL. 2012; 23: 95-95.-14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO); JUN 27-30, 2012; Barcelona, SPAIN. [Poster]
Web of Science

 

Karl, W; Fahrleitner-Pammer, A; Dandachi, N; Strutz, J; Rapp, N; Pieber, TH; Samonigg, H; Balic, M Breast cancer stem cells and their responsiveness to zoledronic acid and anti-RANKL antibody
www.oegekm.at2010; -Wissenschaftliche Herbsttagung der Ögekm ; 26. - 27. November 2010; Vienna. [Poster]

 

Szkandera, J; Ploner, F; Bauernhofer, T; Kasparek, AK; Payer, F; Balic, M; Knechtel, G; Gerger, A; Galle; Samonigg, H; Hofmann, g; Paraneoplastic limbic encephalitis in a patient with extragonadal chorioncarcinoma - the significance of onconeural antibodies: a case report
MEMO Suppl 01/10; 2010; 20-21.-Frühjahrstagung 2010 der Österreichischen Gesellschaft für Hämatologie und Onkologie; APR 8-10; Bregenz, AUSTRIA . [Poster]

 

Balic, M Micrometastases and Cancer Stem Cells; Lethals seeds and the need for supportive soil
; 03.06.2009; University of Miami, Miami, FL, USA. 2009. [Keynote lecture]

 

Balic, M Micrometastases and Cancer Stem Cells: on Lethal Seeds and Supportive Soil
Cambridge Healthtech Institute2009; -Next Generation Dx Summit ; 9-12 August 2009; Washington. [Keynote lecture]

 

Balic, M; Lin, H; Geigl, JB; Zheng, S; Langner, S; Tai, YC; Speicher, MR; Cote, RJ A novel method to capture and characterize bone marrow micrometastases in patients with breast cancer
Abstract Book2009; -7th International Symposium on Minimal Residual Cancer; 16-19 September ; Athens, Greece. [Oral Communication]

 

Balic, M; Rapp, N; Strutz, J; Lin, H; Stanzer, S; Skandera, J; Samonigg, H; Cote, RJ; Dandachi, N Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells
7th International Symposium on Minimal Residual Cancer; SEP 16-19, 2009; Athens, Greece. 2009. [Poster]
FullText

 

Pichler, M; Balic M; Stadelmeyer, E; Ausch, C; Wild, M; Guelly, C; Bauernhofer, T; Samonigg, H; Dandachi, N Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors
joint ZMF & Doctorial Day ; NOV 4-5, 2009; Graz, AUSTRIA. 2009. [Oral Communication]

 

Pichler, M; Balic, M; Stadelmeyer, E; Ausch, C; Wild, M; Gülly C; Bauernhofer, T; Samonigg, H; Hoefler, G; Dandachi, N; Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumours.
Frühjahrstagung 2009 der Österreichischen Gessellschaft für Hmatologie und Onkologie (ÖGHO); APR 16-18, 2009; Salzburg. 2009. [Oral Communication]

 

Szkandera, J; Balic, M; Rapp, N; Strutz, J; Cote, RJ; Samonigg, H Neue Methoden zum Nachweis und Charakterisierung vermeintlicher disseminierter Brustkrebsstammzellen.
MEMO Suppl 02/09; 2009; 2: 1-1.-Frühjahrstagung 2009 der Österreichischen Gesellschaft für Hämatologie und Onkologie; APR 16-18, 2009; Salzburg, AUSTRIA. [Oral Communication]

 

Balic , M; Lin, H; Geilg, JB; Zheng, S; Langner, S; Speicher, MR; Tai, YC; Cote, RJ A novel method to capture and characterize occult bone marrow metastases in patients with breast cancer
Onkologie 20082008; 31 (4 Suplement): -Jahrestagung der österr., deutschen und schweizer Gesellschaft für Hämatologie und Onkologie; Oktober 10-14; Vienna, Austria. [Oral Communication]

 

Balic, M; Lin, H; Geigl, JB; Zheng, S;Langner, S; Speicher, MR; Tai, YC; Cote RJ A novel method to capture and characterize occult bone marrow metastases in patients with breast cancer
AACR Annual Research Meeting 20082008; -AACR Annual Meeting; April 12-16; San Diego, CA, USA. [Poster]

 

Hofmann, G; Dandachi, N; Balic, M; Schippinger, W; Samonigg, H; Regitnig, P; Bauernhofer, T Soluble E-Cadherin and ist prognostic impact on response to neoadjuvant anthracycline-based chemotherapy in breast cancer patients.
Onkologie2008; 31 (suppl 4): 161-162.-Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie; OCT 10-14, 2008; Vienna, AUSTRIA. [Oral Communication]

 

Stanzer, S; Dandachi, N; Balic, M; Bauernhofer, T; Samonigg, H The role of NKG2D expression and soluble MICA and MICB in the higher onset of apoptosis of NK cell subsets in patients with epithelial cancer
WIEN KLIN WOCHENSCHR. 2008; 120(15-16):A46-A46. [Poster]
Web of Science

 

Balic, M Capture and charakterization of disseminated putative breast cancer stem cells
Research visit to Istituto Nationale dei Tumori; Juli 2007; Mailand, Italien. 2007. [Keynote lecture]

 

Schippinger, W; Dandachi, N; Regitnig, P; Hofmann, G; Balic, M; Schug, A; Bauernhofer, T; Samonigg, H Influence of neoadjuvant chemotherapy on the HER-2/neu status of breast cancer tissue.
Supplement 121; 157(25):28-28.-Frühjahrstagung 2007 der Österreichischen Gesellschaft für Hämatologie und Onkologie; April 12-14, 2007; Vienna, AUSTRIA . [Poster]

 

Stanzer, S; Dandachi, N; Balic, M; Janesch, B; Resel, M; Samonigg, H; Bauernhofer, T Higher turnover of NK cells and NK cell subpopulations in patients with metastatic epithelial cancer
World Immune Regulation Meeting; APR 11-15, 2007 ; Davos, Switzerland. 2007. [Poster]

 

Stanzer, S; Dandachi, N; Balic, M; Resel, M; Janesch, B; Samonigg, H; Bauernhofer, T Increase in the Number and Resistance to Programmed Cell Death of CD4+CD25+high regulatory T cells in Patients with Metastatic Epithelial Cancer.
ZMF Tag; OCT 24, 2006; Graz, AUSTRIA. 2006. [Poster]

 

Hofmann, G; Dandachi, N; Balic, M; Schippinger, W; Resel, M; Wernecke, KD; Samonigg, H; Bauernhofer,T; Serum levels of soluble E-cadherin as possible predictive and prognostic marker in female breast cancer patients undergoing neoadjuvant therapy.
Wiener Medizinische Wochenschrift2005; 155(117):2-3.-Frühjahrstagung 2005 der Österreichischen Gesellschaft für Hämatologie und Onkologie (ÖGHO)und der Arbeitsgemeinschaft hämato-onkologischer Pflegepersonen in Österreich ; APR 28-30, 2005; Graz, Austria. [Oral Communication]

 

Hofmann, G; Dandachi, N; Balic, M; Schippinger, W; Wernecke, KD; Samonigg, H; Bauernhofer, T Quantitative measurement of soluble E-cadherin in sera of breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy and its predictive and prognostic value.
J CLIN ONCOL 2005 23: 70S-70S.
Web of Science

 

Samonigg, H; Himmler, G; Gnant, M; Gastl, G; Loibner, H; Possinger, K; Bauernhofer, T; Dandachi, N; Balic, M; Steger, G; Obwaller, A A multicenter phase II, open-label trial of multiple doses of cancer vaccine candidate IGN101 to evaluate efficacy against disseminated tumor cells in blood.
J CLIN ONCOL 2005 23: 180S-180S.
Web of Science

 

Stanzer, S; Dandachi, N; Resel, M; Balic, M; Samonigg, H; Bauernhofer, T; High TurnOver of CD4+CD25+ T cell Subpupulation in patients with Metastatic epithelial cancer
Wiener Medizinische Wochenschrift2005; 155(117):19-20.-Frühjahrstagung 2005 der Österreichischen Gesellschaft für Hämatologie und Onkologie (ÖGHO) und der Arbeitsgemeinschaft hämato-onkologischer Pflegepersonen in Österreich; APR 28-30, 2005; Graz, Austria. [Poster]

 

Eder, T; Andritsch, E; Balic, M; Stöger, H; Samonigg H Durchgangssyndrom bei fortgeschrittener Tumorerkrankung. Differenzialdiagnostische Überlegungen anhand eines Fallberichts.
Kongressband des 50. Ausseer Symposium 2004; -50. Ausseer Symposium; MAY 6-9, 2004; Bad Aussee, AUSTRIA. [Oral Communication]

 

Balic, M; Bauernhofer, T; Hofmann, G; Dandachi, N; Himmler, G; Obwaller, A; Oberkleiner, P; Grunt, S; Loibner, H; Samonigg, H Evaluation of epithelial cell enumeration methods to detect tumor cells of cancer patients
Proc Am Soc Clin Oncol 2003; 22:(abstr 3607): -Annual Meeting of the American Society of Clincal Oncology (ASCO); MAY 31 - JUN 3, 2003; Chicago, Ill., USA. [Poster]

 

Obwaller, A; Balic, M; van der Kooi, A; Dandachi, N; Himmler, G; Mudde, GC; Peball, B; Grunt, S; Oberkleiner, P; Doyle, GV; Terstappen, LWMM; Bauernhofer, T; Samonigg, H; Loibner, H Comparative analysis of three different methods for the detection of disseminated tumor cells
J IMMUNOTHER 2003 26: S49-S50.
Web of Science

 

Samonigg, H; Hofmann, G; Bauernhofer, T; Balic, M; Stöger, H; Groiss, F; Himmler, G; Schuster, M; Rosenkaimer, F; Loibner, H Phase if trial to explore the influence of concomitant chemotherapies on the immunogenicity of the cancer vaccine IGN101 in patients with epithelial cancers
J IMMUNOTHER 2003 26: S14-S14.
Web of Science

 

Samonigg, H; Hofmann, G; Bauernhofer, T; Balic,M; Stoeger, H; Himmler, G; Schuster, M; Rosenkaimer, F; Groiss,F; Loibner, H; Phase II trial to explore the influence of concomitant chemotherapy on the immunogenicity of the cancer vaccine IGN101 in patients with epithelial cancers
Proc Am Soc Clin Oncol 2003; 22:(abstr 683): -Annual Meeting of the American Society of Clinical Oncology (ASCO); May 31-JUN 3, 2003; Chicago, Ill., USA. [Poster]

 

↑ Top of page / Navigation

© Med Uni Graz • Imprint